ZIM LABORATORIES
|
ZIM LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 1.09 | 2.50 | 3.54 | 5.01 | 8.96 |
| CEPS(Rs) | 4.83 | 6.62 | 6.81 | 8.60 | 6.28 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 54.90 | 51.49 | 49.00 | 41.12 | 108.18 |
| Tax Rate(%) | 28.91 | 32.45 | 27.05 | 30.89 | 30.85 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 8.02 | 11.54 | 11.25 | 13.04 | 12.29 |
| EBIT Margin(%) | 5.72 | 7.76 | 8.32 | 10.27 | 8.80 |
| Pre Tax Margin(%) | 2.19 | 4.75 | 6.43 | 8.87 | 6.31 |
| PAT Margin (%) | 1.56 | 3.21 | 4.69 | 6.13 | 4.36 |
| Cash Profit Margin (%) | 6.90 | 8.52 | 9.04 | 10.51 | 9.17 |
| Performance Ratios | |||||
| ROA(%) | 1.15 | 2.64 | 4.38 | 7.14 | 4.37 |
| ROE(%) | 2.14 | 4.97 | 7.86 | 13.00 | 8.65 |
| ROCE(%) | 5.47 | 8.29 | 10.11 | 16.82 | 12.52 |
| Asset Turnover(x) | 0.74 | 0.82 | 0.93 | 1.16 | 1.00 |
| Sales/Fixed Asset(x) | 1.33 | 1.40 | 1.58 | 2.10 | 1.93 |
| Working Capital/Sales(x) | 4.38 | 5.84 | 5.39 | 4.97 | 5.03 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.75 | 0.71 | 0.63 | 0.48 | 0.52 |
| Receivable days | 105.27 | 99.71 | 97.06 | 84.61 | 88.55 |
| Inventory Days | 87.86 | 80.76 | 67.04 | 59.07 | 70.95 |
| Payable days | 157.18 | 143.40 | 128.40 | 127.86 | 166.10 |
| Valuation Parameters | |||||
| PER(x) | 54.87 | 32.12 | 26.98 | 14.44 | 5.95 |
| PCE(x) | 12.41 | 12.11 | 14.02 | 8.42 | 8.49 |
| Price/Book(x) | 1.09 | 1.56 | 1.95 | 1.76 | 1.48 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.07 | 1.32 | 1.53 | 1.02 | 0.92 |
| EV/Core EBITDA(x) | 9.66 | 10.11 | 12.06 | 6.93 | 6.74 |
| EV/EBIT(x) | 18.67 | 17.02 | 18.36 | 9.89 | 10.42 |
| EV/CE(x) | 0.95 | 1.37 | 1.63 | 1.56 | 1.35 |
| M Cap / Sales | 0.86 | 1.03 | 1.27 | 0.89 | 0.78 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -1.22 | 3.16 | -7.80 | 19.52 | 8.52 |
| Core EBITDA Growth(%) | -16.40 | 6.43 | -20.34 | 28.68 | 7.80 |
| EBIT Growth(%) | -27.15 | -3.83 | -25.32 | 39.46 | 38.90 |
| PAT Growth(%) | -52.01 | -29.46 | -29.42 | 67.93 | 98.84 |
| EPS Growth(%) | -56.29 | -29.46 | -29.42 | -44.02 | 98.85 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.42 | 0.45 | 0.44 | 0.30 | 0.29 |
| Current Ratio(x) | 1.45 | 1.39 | 1.43 | 1.72 | 1.45 |
| Quick Ratio(x) | 0.96 | 0.87 | 0.92 | 1.24 | 0.94 |
| Interest Cover(x) | 1.62 | 2.58 | 4.41 | 7.34 | 3.53 |
| Total Debt/Mcap(x) | 0.38 | 0.29 | 0.23 | 0.17 | 0.20 |
Compare Financial Ratios of peers of ZIM LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ZIM LABORATORIES | ₹553.5 Cr | 1.7% | 8% | 18.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹429,145.0 Cr | -0.1% | -2.5% | 6.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,989.0 Cr | -0.2% | -2.8% | 1.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹149,322.0 Cr | 2.3% | 1.2% | 41.1% | Stock Analytics | |
| CIPLA | ₹112,149.0 Cr | 0.7% | 1.9% | -4.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,483.0 Cr | 0.1% | -2.4% | 2.3% | Stock Analytics | |
ZIM LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ZIM LABORATORIES | 1.7% |
8% |
18.8% |
| SENSEX | -1% |
-5.7% |
-9.7% |
You may also like the below Video Courses
